Jazz Pharmaceuticalsの空売り状況は、投資家がJazz Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Jazz Pharmaceuticals (NASDAQ:JAZZ) 株価情報, 空売り情報

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and lowers the price target from $167 to $155.

News

Price Target

Analyst Ratings

JAZZ

Baird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $155

RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and lowers the price target from $182 to $172.

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172

WIIM

Jazz Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS guidance. Also, Piper Sandler and Morgan Stanley lowered their respective price targets on the stock.

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $176 to $147.

Reiteration

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $147

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $183 to $166.

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $166

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $200 price target.

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target

Jazz Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS guidance.

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) lowers FY2025 Adj EPS guidance from $22.50-$24.00 to $4.00-$5.60 vs $23.25 analyst estimate. Affirms FY2025 sales outlook from $4.15 billion-$4.40 billion to $4.15 billion-$4.40 billion vs $4.29 billion estimate.

Guidance

Jazz Pharmaceuticals Lowers FY2025 Adj EPS Guidance from $22.50-$24.00 to $4.00-$5.60 vs $23.25 Est; Affirms FY2025 Sales Guidance of $4.15B-$4.40B vs $4.29B Est

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) reported quarterly earnings of $1.68 per share which missed the analyst consensus estimate of $4.66 by 63.95 percent. This is a 37.31 percent decrease over earnings of $2.68 per share from the same period last year. The company reported quarterly sales of $897.84 million which missed the analyst consensus estimate of $985.39 million by 8.88 percent. This is a 0.46 percent decrease over sales of $901.98 million the same period last year.

Earnings

Earnings Misses

Jazz Pharmaceuticals Q1 Adj. EPS $1.68 Misses $4.66 Estimate, Sales $897.84M Miss $985.39M Estimate

- Court Filing 
Case: 24-2277

Legal

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

A U.S. Federal Appeals Court Has Partially Overturned A Lower Court's Injunction, Allowing Avadel Pharmaceuticals To Seek FDA Approval And Market Its Narcolepsy Drug, Lumryz, For Idiopathic Hypersomnia

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Jazz Pharmaceuticals to report an earnings per share (EPS) of $4.76.
Anticipation surrounds Jazz Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.79, which was followed by a 3.22% increase in the share price the next day.
Here's a look at Jazz Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.81</td>
<td>5.50</td>
<td>4.8</td>
<td>4.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>6.60</td>
<td>6.61</td>
<td>5.3</td>
<td>2.68</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>7.000000000000001%</td>
<td>4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746453785_0.png" alt="eps graph" />
<h3>Market Performance of Jazz Pharmaceuticals's Stock</h3>
Shares of Jazz Pharmaceuticals were trading at $120.05 as of May 02. Over the last 52-week period, shares are up 7.78%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Jazz Pharmaceuticals</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Jazz Pharmaceuticals.
A total of 13 analyst ratings have been received for Jazz Pharmaceuticals, with the consensus rating being Buy. The average one-year price target stands at $194.0, suggesting a potential 61.6% upside.
<h3>Comparing Ratings with Competitors</h3>
The below comparison of the analyst ratings and average 1-year price targets of Corcept Therapeutics, Axsome Therapeutics and Elanco Animal Health, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Corcept Therapeutics, with an average 1-year price target of $120.12, suggesting a potential 0.06% upside.</li>
<li>Analysts currently favor an Buy trajectory for Axsome Therapeutics, with an average 1-year price target of $179.12, suggesting a potential 49.2% upside.</li>
<li>Analysts currently favor an Buy trajectory for Elanco Animal Health, with an average 1-year price target of $15.0, suggesting a potential 87.51% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Corcept Therapeutics, Axsome Therapeutics and Elanco Animal Health, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>Buy</td>
<td>7.53%</td>
<td>$959.46M</td>
<td>4.62%</td>
</tr>
<tr>
<td>Corcept Therapeutics</td>
<td>Buy</td>
<td>34.33%</td>
<td>$178.93M</td>
<td>4.61%</td>
</tr>
<tr>
<td>Axsome Therapeutics</td>
<td>Buy</td>
<td>66.04%</td>
<td>$108.25M</td>
<td>-99.94%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Buy</td>
<td>-1.45%</td>
<td>$519M</td>
<td>-0.13%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Jazz Pharmaceuticals ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the bottom compared to its peers.
<h3>Unveiling the Story Behind Jazz Pharmaceuticals</h3>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jazz Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.53%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 17.56%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 4.62%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Jazz Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.57%, the company showcases efficient use of assets and strong financial health.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 1.51. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/JAZZ/earnings">To track all earnings releases for Jazz Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Jazz Pharmaceuticals's Earnings

DUBLIN, April 25, 2025 /PRNewswire/ --&nbsp;Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.
The CHMP's recommendation will now be reviewed by the European Commission which has the authority to approve medicines in all EU Member States, Iceland, Norway, and Liechtenstein, and is expected to make a final decision.
 &nbsp;
 &nbsp;

Jazz Pharma Secures CHMP Support for Zanidatamab for Treatment of Advanced HER2-Positive Biliary Tract Cancer

13 analysts have expressed a variety of opinions on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $194.0, along with a high estimate of $230.00 and a low estimate of $150.00. Observing a 6.55% increase, the current average has risen from the previous average price target of $182.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311642_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $217.00&#x7C;$200.00 &#x7C; 
&#x7C;Jeffrey Hung &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $183.00&#x7C;$175.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $179.00&#x7C;$145.00 &#x7C; 
&#x7C;Gregory Fraser &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $230.00&#x7C;$220.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $200.00&#x7C;$190.00 &#x7C; 
&#x7C;Charles Duncan &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Neutral &#x7C; $150.00&#x7C;$140.00 &#x7C; 
&#x7C;David Amsellem &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $176.00&#x7C;$163.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $178.00&#x7C;$179.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $209.00&#x7C;$200.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $210.00&#x7C;$205.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $170.00&#x7C;$130.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Jazz Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Unraveling the Financial Story of Jazz Pharmaceuticals</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Jazz Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 7.53% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 4.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.57% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.51.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Jazz Pharmaceuticals Stands With Analysts

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $210 price target.

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target

As Jazz Pharmaceuticals plc (the "Company") has previously disclosed, a number of complaints, including, from June 2020 to September 2020, several complaints styled as class actions and, from March 2021 to May 2022, several additional complaints, were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the Company's actions leading up to, and entering into, patent litigation settlement agreements with generic drug manufacturers who had filed abbreviated new drug applications ("ANDAs" and such filers, "ANDA filers"), violate U.S. state and federal antitrust, consumer protection and unfair competition laws. This group of cases was consolidated for multidistrict litigation ("MDL") proceedings before the U.S. District Court for the Northern District of California (the "Court") in December 2020.
On April 7, 2025, Jazz Pharmaceuticals Ireland Limited, a wholly-owned subsidiary of the Company, entered into a preliminary class settlement agreement (the "preliminary class settlement agreement") with the class of indirect Xyrem purchasers to settle all claims of participating class members against the Company with respect to the Company's actions leading up to, and entering into, patent litigation settlement agreements with the ANDA filers.
Pursuant to the preliminary class settlement agreement, which was entered into with counsel representing the class representatives, the Company has agreed to pay a total of $145&nbsp;million in a lump sum. The Company plans to use cash on hand to fund the preliminary class settlement agreement's obligations. The Company expects to record a pre-tax charge of approximately $145&nbsp;million associated with this preliminary class settlement agreement in the first quarter of 2025.

Jazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays raised Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) price target from $39 to $41. Barclays analyst Matt Miksic maintained an Overweight rating. Baxter International shares closed at $36.57 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/BAX/analyst-ratings">view this stock</a>.</li>
<li>Barclays boosted the price target for Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) from $940 to $980. Barclays analyst Karen Short maintained an Equal-Weight rating. Costco shares closed at $964.31 on Friday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised SLM Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) price target from $32 to $38. Morgan Stanley analyst Jeffery Harte maintained an Overweight rating. SLM shares closed at $29.46 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/SLM/analyst-ratings">view this stock</a>.</li>
<li>B of A Securities slashed the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $333 to $318. B of A Securities analyst Joshua Shanker maintained a Buy rating. Progressive shares closed at $279.82 on Friday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for WillScot Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) from $38 to $32. Baird analyst Andrew Wittmann maintained a Neutral rating. WillScot Holdings shares closed at $28.07 on Friday. <a href="https://www.benzinga.com/quote/WSC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) price target from $200 to $217. HC Wainwright &amp; Co. analyst Oren Livnat maintained a Buy rating. Jazz Pharmaceuticals shares settled at $138.81 on Friday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) price target from $13.7 to $29. Citigroup analyst Jeff Chung upgraded the stock from Neutral to Buy. XPeng shares closed at $23.60 on Friday. <a href="https://www.benzinga.com/quote/XPEV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut The Sherwin-Williams Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) price target from $423 to $380. Jefferies analyst Laurence Alexander downgraded the stock from Buy to Hold. Sherwin-Williams shares closed at $363.62 on Friday.  <a href="https://www.benzinga.com/quote/SHW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark raised the price target for DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) from $44 to $51. Benchmark analyst Mike Hickey maintained a Buy rating. DraftKings shares settled at $39.41 on Friday. <a href="https://www.benzinga.com/quote/dkng/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies raised Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) price target from $165 to $185. Jefferies analyst John Colantuoni upgraded the stock from Hold to Buy. Airbnb shares closed at $134.39 on Friday. <a href="https://www.benzinga.com/quote/abnb/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Trading Ideas

ABNB

COST

DKNG

XPEV

DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday

HC Wainwright &amp; Co. analyst Oren Livnat maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and raises the price target from $200 to $217.

HC Wainwright & Co. Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $217

Morgan Stanley analyst Jeffrey Hung assumes Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight rating and raises Price Target to $183.

Initiation

Morgan Stanley Assumes Jazz Pharmaceuticals at Overweight, Raises Price Target to $183

UBS analyst Ashwani Verma upgrades Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Neutral to Buy and raises the price target from $145 to $179.

Upgrades

UBS Upgrades Jazz Pharmaceuticals to Buy, Raises Price Target to $179

Press Releases

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting

Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

CMRX

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Jazz Pharmaceuticals

空売り

Jazz Pharmaceuticals (NASDAQ:JAZZ) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル